Sarah Cannon Research Institute

Site:	Sarah Cannon Research Institute	Go to their website
Address:	3322 West End Avenue Suite 900
City:	Nashville
State:	TN
Zip:	37203
Country:	USA

14 trials at this site

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
1/2	Phase I/II Study of PDR001 in Patients With Advanced Malignancies	Active, not recruiting	Closed	PDR001	NCT02404441
1	DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	DS-6157a	NCT04276415
2	Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor	Completed	Closed	AUY922	NCT01404650
2	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	Closed	Dovitinib	NCT01831726
1	Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies	Completed	Closed	SNX-5422	NCT00506805
1	A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors	Completed	Closed	HSP990	NCT00879905
1	A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma	Completed	Closed	GDC-0980	NCT00854152
1	A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors	Completed	Closed	GDC-0941 + GDC-0973	NCT00996892
1	Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	Completed	Closed	MSC1936369B + SAR245409	NCT01390818
1	A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer	Ongoing, but not recruiting	Closed	BEZ235	NCT00620594
1	A Phase IA, Multi-Center, Open-Label, Dose- Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients with Advanced Solid Malignancies	Ongoing, but not recruiting	Closed	BKM120
1	Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506) + Moxifloxacin	NCT01339104
1	A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors	Ongoing, but not recruiting	Closed	GDC-0973 + GDC-0068	NCT01562275
1	A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	KTN0158	NCT02642016